The company’s Blujepa is the first in a new class of oral antibiotics for UTIs in nearly 30 years and was designed to fight the common condition with a lower potential for antimicrobial resistance More: GSK ushers in new UTI
read moreFast-rising New York City central nervous system specialist Axsome has scored in a phase 3 trial testing Sunosi on adults with attention deficit hyperactivity disorder (ADHD). More: Axsome touts success of phase 3 trial of Sunosi in ADHD, adding to
read moreEisai ran a simulation projecting that Leqembi sales for fiscal year 2027, which wraps up in March 2028, will reach 250 to 280 billion yen ($1.6 billion to $1.8 billion). More: Eisai lays out road map to blockbuster sales projections
read moreShortly after WuXi AppTec offered an upbeat outlook for 2025, other WuXi companies are touting their own 2024 success stories and ambitions for 2025. More: Contractors WuXi Bio, WuXi XDC eye continued growth after logging solid performances in 2024 Source:
read moreAfter threatening a month ago to impose “25% or higher” tariffs on foreign-made pharmaceuticals, President Donald Trump has doubled down on the pledge, although the exact timing and scope of their implementation remains unclear. More: Trump again threatens tariffs on
read more
Pfizer’s Abrysvo is designed to prevent RSV-associated disease in infants More: WHO adds first maternal RSV vaccine to prequalification list Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals